There is little information on the progression of peripheral arterial disease (PAD) over time. A series of 508 patients with a prior examination for PAD were contacted and brought in for follow-up to evaluate the natural history of PAD. A total of 85 patients were excluded because they had interventions in both limbs prior to their return visit. Progression was assessed in the remaining 423 patients for a total of 755 limbs, both quantitatively and qualitatively using six categories of PAD severity. There was a modest overall categorical progression of disease: 228 limbs (30.2%) displayed categorical progression, while 172 limbs (22.8%) improved over a 4.6-year average follow-up. Through analysis of quantitative change, it was determined that more quantitative progression occurred than was evident from categorical progression. Two of the three non-invasive tests employed, the ankle/brachial index (ABI) and posterior tibial peak forward flow velocity (peak PT), showed statistically significant progression during follow-up: mean ABI change = −0.019, 95% confidence interval (CI) = −0.031 to −0.007; mean peak PT change = −2.32 cm/s, 95% CI = −3.20 to −1.44. The toe/brachial index (TBI) also suggested progression: mean change = −0.013, but the 95% CI included no change. Standard scores (sum of the Z-scores for ABI, peak PT and TBI) were calculated. The standard score progressed approximately 0.34 units (standard deviations), p-value Ͻ0.001, over 4.6 years; or about 0.07 standard deviations per year. There were independent and statistically significant (p Ͻ 0.05) associations between the rate of PAD progression (standard score change) and age, diabetes, classic ('Rose') intermittent claudication, moderate to severe PAD in the same limb, moderate to severe PAD in the contralateral limb and future therapeutic intervention. There were independent and suggestive associations (0.05 Ͻ p-value Ͻ 0.15) between PAD progression and pain at rest, mild PAD in the same limb, and mild PAD in the contralateral limb. PAD progression was not associated with gender, atypical claudication, or amputation status.
Introduction
Studies evaluating the natural history of peripheral arterial disease (PAD) have typically analyzed PAD with regard to associated morbidity and mortality. 1 Very few studies have looked at the progression (or regression) of PAD severity over time in a cohort of patients. The majority of such studies have dealt with surrogate measures of disease severity such as changes in intermittent claudication, the development of gangrene or ulceration, or the requirement for angioplasty, vascular reconstruction or amputation. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] A small number of studies have looked at the progression of PAD via serial angiographic measurements of lesion severity or a combination of angiography, non-invasive testing and surrogate endpoints. [13] [14] [15] [16] [17] Two studies have analyzed PAD progression in selected patients using serial measurement a Department of Family and Preventive Medicine and b Department of Surgery and Bio-Engineering, University of California, San Diego, La Jolla, CA, USA of the ankle/brachial index (ABI). 18, 19 To the authors' knowledge, no previous study has systematically assessed quantitative PAD progression in non-selected patients, both symptomatic and asymptomatic, using a battery of noninvasive tests. Reported here is the quantitative and qualitative progression of PAD, and predictors of this change, as measured by non-invasive testing in 508 patients followed-up for an average of 4.6 years.
Methods

Data collection
Between 1990 and 1994, patients seen in the previous 10 years for non-invasive lower extremity arterial testing at the San Diego Veterans Administration Medical Center (VAMC) or the University of California, San Diego Medical Center (UCSDMC) vascular laboratories were invited to return for a new, non-invasive vascular examination of the lower extremities using the same testing procedure. The major goal of the study was to investigate the natural history of PAD. Of 2265 patients with vascular laboratory visits in this time period, 481 were deceased and another 1276 did not participate. Thus, 508 patients returned for inter-views and clinical evaluation. The study population consisted of those patients who had survived, could be located and were willing to participate.
The subjects who agreed to undergo repeat testing for PAD signed a consent form approved by the University of California, San Diego IRB, and were interviewed in person using a structured questionnaire. A non-invasive vascular examination including segmental blood pressures and flow velocities was performed. This new visit was called the 'follow-up visit'. Data from all previous vascular laboratory examinations were abstracted and recorded.
For subjects who had undergone an intervention (either angioplasty or surgery) at any time prior to their follow-up visit, an intervention-free follow-up period was determined (when possible). For these patients, the follow-up values were taken to be the values for their VAMC or UCSDMC vascular laboratory visit immediately preceding their intervention; i.e. patients who had an intervention prior to the follow-up visit but had at least two vascular laboratory visits on record that preceded any intervention were retained in the data set along with patients with no history of intervention. Of the 508 VAMC and UCSDMC PAD patients participating in the study, 85 had an intervention (angioplasty, vascular reconstruction, or amputation) in both limbs prior to the follow-up visit and had no intervention-free period that could be evaluated. Thus, 423 PAD patients provided follow-up data on at least one limb prior to any intervention and could be included in these analyses: 331 patients from the VAMC and 92 from UCSDMC. Data from a total of 755 limbs with at least some interventionfree follow-up were available for analysis. This paper addresses limb-specific rather than patient-specific results.
Non-invasive tests
Blood pressures were measured at both ankles and both toes using the sphygmomanometric technique with detection at the toe by photoplethysmography. Bilateral brachial pressures were also determined sphygmomanometrically by detection at the third finger by photoplethysmography. Photoplethysmographic assessment has been shown to give essentially identical results to Doppler signal determination in both the arms and legs. 20 Flow velocities of the posterior tibial artery were measured by Doppler ultrasonography using the 'maximum amplitude search' technique. 21, 22 The ankle/brachial index (ABI), toe/brachial index (TBI) and the peak posterior tibial forward flow velocity (peak PT) were recorded. The ABI and TBI were calculated using the arm with the higher systolic blood pressure. The reproducibility of each of these three tests has been reported. For the ABI, the 95% confidence interval (CI) of reproducibility has been reported to be in the 0.10 to 0.15 range. [23] [24] [25] For the peak PT, triplicate measurements on 20 normal legs showed all three values to be within one standard deviation. 22 Variability in the TBI is greater, and has been reported to be anywhere from the same range as the ABI 26 to about twice that of the ABI. 24 This greater variability is consistent with the higher susceptibility to vasoreactivity in the toe. 27 Previously published data for large vessel (LV)-PAD reports that the combination of the ABI and peak PT had a sensitivity of 89%, a specificity of 99%, a positive predictive value of 90%, a negative predictive value of 99%, and an overall accuracy of LV-PAD of 98% when compared with an entire battery of tests using five levels Vascular Medicine 1999; 4: [15] [16] [17] [18] [19] [20] [21] of segmental pressures and three measures of blood flow in the posterior tibial and femoral arteries. 28 The baseline and follow-up ABI and TBI were restricted to a maximum value of 1.15 to avoid bias from falsely high pressures that can develop from arterial stiffening.
PAD classification
The PAD patients were categorized (by limb) at baseline and follow-up as normal, isolated small vessel (ISV)-PAD, or LV-PAD, based on the non-invasive tests. Criteria were:
Normal: an ABI Ͼ 0.90 and a peak PT Ͼ 10 cm/s and a TBI Ͼ 0.70. ISV-PAD: a TBI р 0.70 and an ABI Ͼ 0.90 and a peak PT Ͼ 10 cm/s. LV-PAD: an ABI р 0.90 or a peak PT р 10 cm/s. An ABI cut-off of 0.90 was utilized because this value has become the conventional cut-off point for PAD in vascular laboratories. Patients with ABI values р0.90 were further categorized into three groups based on severity: (1) ABI 0.81-0.90; (2) ABI 0.61-0.80; (3) ABI р0.60. Patients with an ABI Ͼ0.90 but a peak PT р10 cm/s were classified as isolated posterior tibial disease (IPT). 29, 30 ISV-PAD was defined as a normal ABI and peak PT, with an abnormal TBI, because in theory such findings could be due to isolated poor perfusion in small vessels. 31 Any limb with one of these three tests missing, but normal on the other two tests, was classified as unknown and excluded from the analyses.
Symptom classification
During the patient interview, the patient was asked to complete the San Diego Claudication Questionnaire (SDCQ). 30 This questionnaire specifically addresses pain in the buttocks, thighs and calves while at rest and while walking, and whether the pain was located in the right or left leg, or bilaterally. Unlike the Rose questionnaire 32 and the Edinburgh questionnaire, 33 the SDCQ allows lateralization of all symptoms. From these questions it was possible to categorize each patient limb into one of five symptom categories: (1) no pain; (2) pain at rest; (3) non-calf exercise leg pain; (4) 'non-Rose' exercise calf pain; and (5) 'Rose' claudication. 30 The term 'pain at rest' was specifically chosen to distinguish this category from 'rest pain', which in PAD typically refers to severe ischemic pain present even without exercise. In contrast, 'pain at rest' refers to any leg pain that is present at rest. The non-calf exercise leg pain and 'non-Rose' exercise calf pain categories were combined into a 'possible claudication' category for these analyses.
Analysis
The data set was analyzed using SAS and SPSS statistical software. The distributions of the key variables used in PAD classification were inspected for normality. The baseline characteristics of the study subjects were compared with those of a sample of non-participants to evaluate the likelihood and extent of possible selection bias.
Qualitative change in PAD type was analyzed by creating a 6 by 6 table of baseline by follow-up PAD classification of the limbs available for analysis. The percentage of limbs that 'progressed' (non-invasive test results worsened) or 'regressed' (non-invasive test results improved) by one or more categories was calculated. To analyze quantitative change, Z-scores were obtained for the ABI, peak PT and TBI values for each limb at baseline and follow-up using the baseline mean and standard deviation. The Z-scores were summed for each limb to obtain a standard score for both the baseline and follow-up visits. The change in standard score reflects the average change in PAD over time in a given limb. These standard score values were utilized in univariate and multivariate linear regression models to analyze the quantitative change in PAD severity. One standard deviation was defined as one 'unit'.
Because the two limb values for a patient tended to be correlated, models were evaluated using, alternatively, one limb or both limbs as dependent variables. The beta coefficients and p-values were nearly identical for both types of model, indicating that regression of person-specific variables (e.g. age and gender) on limb-specific values was appropriate.
Results
Non-participant comparison
Of the eligible non-participants, abstracted baseline information was obtained on 77 surviving patients. The descriptive statistics for the abstracted non-participants given below can be compared with the values for the study subjects in Tables 1, 2 and 3. A total of 92% of the non-participants were male, versus 87% of the study subjects. The mean age of the non-participants at the midpoint of the study was 70 years, which was similar to the study subjects' 69 years. In the non-participants group, 54.3% of limbs had LV-PAD, 27.8% had ISV-PAD and 17.9% were normal, compared with respective frequencies of 50.5%, 14.0% and 35.5% in the study subjects. In the non-participants group, the mean baseline ABI, peak PT and TBI were 0.85, 17 and 0.63, compared with respective values of 0.90, 19 and 0.68 in the study subjects. These results suggest that the participants had slightly less advanced disease than the nonparticipants, but were otherwise comparable. Table 1 displays the limb-specific frequencies of the categorical variables for the study population. About half of the patients were Ͻ70 years of age. Of the 755 limbs, 15 limbs (2.0%) required amputations at the level of the toe or above, 240 limbs (31.8%) were from self-reported current diabetic patients and 40 (5.3%) went on to have intervention between the time of their baseline and follow-up visits. The Numbers are the number of limbs; % are given in parentheses. ISV, isolated small vessel; IPT, isolated posterior tibial; ABI, ankle/brachial index; LV, large vessel. majority of the limbs (661; 87.5%) were from male patients; 506 limbs (67.0%) were symptomatic at the time of the follow-up visit (26.2% with pain at rest, 17.4% with possible claudication, and 23.4% with Rose claudication). In epidemiologic studies, fewer than half of all people with PAD will have leg symptoms. 29 The higher rate here reflects the selective referral of symptomatic patients for vascular laboratory examination.
Descriptive statistics
Since diabetes mellitus was quite common in these PAD patients, the differences between current self-reported diabetics and other patients was evaluated. Patients from the diabetic group had the same sex ratio as non-diabetics but were somewhat younger (x = 66.8 versus 69.5 years, p Ͻ 0.001) and somewhat more symptomatic (74.0 versus 65.5%, p = 0.02). Diabetic limbs required amputation more frequently than non-diabetic limbs (4.5% versus 0.8%, p = 0.002). Therefore, it was estimated that a limb of a diabetic patient was approximately six times more likely to be amputated than a limb of a non-diabetic patient after adjusting for age and gender.
Categorical change
PAD categories at follow-up were stratified by the baseline categories ( Table 2) . A total of 82.4% (314/381) of the LV-PAD limbs at baseline were still classified LV-PAD at follow-up, but only 66.0% (177/268) of the baseline normal limbs were classified normal at follow-up. Table 2 provides information on categorical progression within sub-categories of PAD. Based on the earlier population study data correlating categories of PAD with symptoms and survival, 34 severity of PAD was defined in the following order, going from least to most severe: ISV, IPT, ABI 0.81-0.90, ABI 0.61-0.80 and ABI р 0.60. Overall, 30.2% (228/755) limbs progressed by one or more categories, while 22.8% (172/755) regressed by one or more categories. IPT limbs were substantially more likely to progress to an abnormal ABI than either normal or ISV limbs, but less likely to worsen than any abnormal ABI category, even the 0.81 to 0.90 category. As categories of ABI become more severe, regression to either ISV or normal findings was progressively less likely. Such regression occurred in 32.4% of ABI 0.81-0.90 limbs, 11.0% of ABI 0.61-0.80 limbs and only 4.7% of ABI р 0.60 limbs. Table 3 demonstrates that over an average 4.6-year followup, PAD was not a static disease in that the mean absolute changes for the three non-invasive tests were each greater than zero. Progression of disease is indicated by negative change values, since change equals the follow-up value minus the baseline value. The ABI, peak PT and TBI worsened, with changes of −0.02, −2.32 cm/s, and −0.01, respectively. The mean standard score deteriorated by 0.34 units (standard deviations). At younger and older ages and in both genders, the mean change in ABI remained fairly constant with a progression of approximately −0.02 (not shown). However, the mean changes in peak PT, TBI and standard score showed some variability by age. Peak PT showed a progression of approximately −1.5 cm/s for those in the 70+ age group, versus −3.0 cm/s for those less than 70 years of age. For the TBI, patients less than 70 years of age displayed a regression of approximately 0.02, while those in the 70+ age group displayed a progression of approximately −0.05. The standard score displayed almost no variation in the mean change by gender (progression of −0.33 units for females and −0.34 units for males), but had variability by age group (progression of −0.25 units for patients less than 70 years of age versus −0.44 units for those in the 70+ age group). The correlations between changes in the three non-invasive tests were highly statistically significant (p-values р0.01) but had modest absolute values ranging from 0.10 to 0.51 (not shown). On the other hand, the correlations between changes in each of the non-Vascular Medicine 1999; 4: [15] [16] [17] [18] [19] [20] [21] invasive tests and the standard score change were quite high, ranging between 0.68 and 0.73, p Ͻ 0.0001 (not shown).
Quantitative change
Statistical models
To analyze the quantitative change in PAD, univariate and multivariate linear regression models were fitted with the limb-specific follow-up standard score as the dependent variable, and with the independent variables of age, gender, diabetes status, future intervention, amputation status, symptomatology, limb PAD diagnosis, contralateral limb PAD diagnosis, follow-up duration and baseline standard score (to adjust for regression to the mean). The beta coefficients, p-values and confidence intervals of the final multivariate model are presented in Table 4 . The beta coefficients for age, follow-up time and standard score at baseline are per unit indicated. For the other variables the beta coefficients are for categorical comparisons.
All of the significant variables were inversely correlated with the follow-up standard score (except the baseline standard score, as expected). That is, the greater the value of the given variable the greater the decline in the follow-up standard score. The baseline standard score was positively correlated with the follow-up standard score, but the slope (beta coefficient) was Ͻ1.0, suggesting some regression to the mean.
On average, after adjusting for all other variables in the model, a 5-year age increment was associated with a statistically significant (p-value Ͻ0.05) approximate −0.15 unit progression of the follow-up standard score. A 5-year follow-up duration was associated with an approximate −0.45 unit progression. A baseline diagnosis of LV-PAD was associated with an approximate −0.90 unit progression while a contralateral limb baseline diagnosis of LV-PAD was associated with an approximate −0.85 unit progression. A baseline diagnosis of ISV-PAD and a contralateral limb baseline diagnosis of ISV-PAD were suggestive (borderline significance, 0.05 Ͻ p-value Ͻ 0.25) of progression of approximately half the magnitude associated with the respective LV-PAD diagnosis. Diabetes was associated with an approximate −0.40 unit progression compared with non-diabetics, future intervention was associated with an approximate −1.75 unit progression, 'Rose' claudication at follow-up was associated with an approximate −1.00 unit progression and pain at rest was associated with an approximate −0.40 unit progression, compared with those who were symptom-free. Amputation status and possible claudication were suggestive of a deterioration of the follow-up standard score in both the univariate and multivariate analyses. There was no association (p-value Ͼ0.25) between gender and follow-up standard score in either the univariate or the multivariate models.
Discussion
The study population appeared to be representative of PAD patients seen in hospital vascular laboratories who have survived an average of 5 years; patients were primarily older males with borderline to abnormal non-invasive testing results for PAD. The closeness of the mean ABI, peak PT and TBI values to clinical PAD endpoints for each measurement is not surprising given that the study's criteria for study participation was referral to a vascular laboratory for PAD testing. Nonetheless, there is a large number of normal limbs in this analysis, reflecting unilateral disease in many patients and non-vascular disorders in a few patients. In this population, 27.5% of the patients had bilateral normal limbs at baseline, but at follow-up only 19.9% of patients remained normal bilaterally. Finally, comparison of available baseline information from non-participants suggests that study subjects were reasonably representative of PAD patients. Several investigators have found that PAD progresses over time. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [35] [36] [37] Dormandy et al state that there is general agreement that only about 25% of PAD patients will significantly deteriorate symptomatically over time, but that the underlying atheromatous disease almost certainly progresses. 1 Categorical progression of PAD severity has been demonstrated in a few studies, 7, 14, 17, 18 with the estimates ranging between a low of 2.5% per year developing rest pain or gangrene reported by Jelnes et al, 7 Table 3 indicates that substantial numbers of limbs in the IPT and ISV categories at baseline 'regressed' to normal. Nonetheless, 28.3% of the ISV category and 22.2% of the IPT category retained these diagnoses, and about one-third of both the ISV and the IPT limbs worsened. This suggests that some ISV and IPT limbs may reflect a transient vasoactive process, while others represent early PAD that will progress. Alternatively, the development of collaterals could lead to 'regression'. These two PAD categories are currently being further analyzed.
When looking at categorical change in disease classification, the amount of progression is not as great as that seen when examining quantitative change in PAD severity. Since a patient's limb that is classified as LV-PAD at baseline and demonstrates quantitative progression of disease will still be classified as LV-PAD at follow-up, the proportion of limbs displaying categorical change is always less than the proportion of limbs with quantitative change. Therefore, quantitative assessment is a more accurate approach to measuring change in PAD severity. In this study, the authors found an average progression in the ABI, peak PT and TBI of approximately −0.02, −2.32 cm/s and −0.01 respectively, over a 4.6-year follow-up. On the other hand, Fowkes et al found that the ABI progressed about −0.01 per year. 19 This discrepancy could be accounted for in part by limbs progressing to the point of requiring intervention rapidly after diagnosis, and thus necessarily being excluded from these analyses. In fact, Jelnes et al showed that progression occurred at a rate approximately three times greater in the first year following diagnosis than in subsequent years. 7 Therefore, the results may underestimate the rate of quantitative progression in patients who require intervention in the first year following diagnosis of PAD. However, given that only a small proportion of PAD patients fall into a rapid deterioration group, the estimates should be generalizable to the majority of PAD patients. The average progression in standard score change was approximately −0.34 standard deviations over a 4.6-year follow-up, or approximately −0.074 SD per year.
Several studies have determined that the ABI (or the ankle systolic blood pressure) was significantly associated with progression of PAD. 5, 7, 9, 18, 19, [35] [36] [37] In addition to ABI, Christensen et al found that progression was associated with toe pressure, 37 and Fowkes et al found that progression was associated with the age of the patient. 19 Furthermore, Walsh et al found that stenoses progressed more rapidly in the limbs of patients whose contralateral superficial femoral artery was occluded. 17 In the present study, it was found that progression of PAD was associated with older age, longer follow-up duration, diabetes, future intervention, baseline LV-PAD diagnosis and contralateral limb baseline LV-PAD, and Rose claudication. The fact that Rose claudication is predictive of the rapidity of PAD progression, independent of the non-invasively determined severity of PAD at baseline, emphasizes the importance of obtaining leg-specific reporting of claudication symptoms from PAD patients. The prediction of standard score change by future intervention was expected, because non-invasive studies indicating severe disease or worsening values could be indicators for intervention.
One of the drawbacks of longitudinal analysis of any quantitative measurement is that regression to the mean will occur. That is, with any clinical measurement, some random error is unavoidable and extreme values tend to be closer to the average when remeasured. This bias tends to be non-systematic and thus will usually lead to underestimation of the mean change, requiring statistical adjustment for the baseline value. On the other hand, arterial wall stiffening is a systematic bias in the measurement of systolic blood pressure and thus tends to limit the ability to diagnose PAD in patients in whom it occurs. By setting an upper limit on both the ABI and TBI of 1.15 we lessened, but could not eliminate, the systematic bias associated with arterial wall stiffening. In addition, the exclusion of the rapid deterioration group (e.g. patients who received intervention immediately following their initial vascular laboratory study) would tend to underestimate quantitative progression. Finally, PAD probably progressed more quickly in patients who died before a follow-up examination could be completed. Therefore, for the above reasons (arterial wall stiffening, early intervention and selective survival), it is considered that the overall effect of bias results in an underestimation of the magnitude of quantitative progression in this study.
PAD patients showed an average quantitative progression of approximately 7% of a standard deviation per year. This estimate suggests that the underlying atheromatous process does indeed progress over time in the average patient. Therapy designed to slow atherosclerotic plaque formation or reduce the risk factors associated with atherosclerosis should reduce the morbidity and mortality associated with PAD. Given the non-invasive nature of vascular laboratory studies and the good agreement between the results obtained in this study and those reported in earlier studies, it is felt that serial non-invasive testing could be Vascular Medicine 1999; 4: 15-21 used in clinical trials as an indicator of disease progression, and as an estimate of the effectiveness of treatment.
